跳至主要内容
临床试验/EUCTR2007-000390-31-DE
EUCTR2007-000390-31-DE进行中(未招募)不适用

Application of hypertonic hyperoncotic solutions for improvement of cardiac output after open heart surgery in children - monocentric, randomised, placebo controlled, double-blind clinical trial (phase IV) - HyperHAES-PÄD-CARDIO-02

niversitätsklinikum Erlangen0 个研究点开始时间: 2009年7月28日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Written informed consent of the legal guardian and consent of the patient, if applicable
  • Age: 1 month to 5 years
  • Patients with up to now untreated cyanotic or acyanotic organic heart defects, after open-heart surgery with cardio-pulmonal-bypass
  • Body weight: > 3,5 kg up to < 50 kg
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Age > 5 years
  • Body weight < 3,5 kg or >50 kg
  • Known hypersensitivity against hydroxyethyl starch in the patient's history
  • Evidence in the patient's history of hemorrhagic diathesis
  • Pre-surgical manifest heart insufficiency (NYHA-classification: degree IV)
  • Thrombopenia (Thr <50000/mm3) at study inclusion
  • Restricted renal function
  • (creatinin-clearance acc. to Schwartz < 30 ml/min/1,73 m2)
  • Pre-surgical Na > 150 mmol/l
  • Pre-surgical hyperchloremia
  • Calculated serum osmolarity:> 350 mosm/l
  • Acute life threatening hypovolemic shock
  • Dehydration
  • Hyperhydration
  • Oliguria/Anuria
  • Known disturbance of haemostasis
  • Contraindications in the product information (SmPC) of HyperHAES® or Isotonische Kochsalzlösung Fresenius® do apply
  • participation in another clinical trial with an investigational medicinal product.

研究者

发起方
niversitätsklinikum Erlangen

相似试验